下一代糖尿病治疗和药物传输市场－全球产业规模、份额、趋势、机会及预测（按产品类型、适应症、最终用户、地区和竞争格局划分，2021-2031年）

全球下一代糖尿病治疗和药物输送市场预计将从 2025 年的 238.6 亿美元增长到 2031 年的 363.1 亿美元，复合年增长率为 7.25%。

此细分市场包括新型胰岛素类似物和Glucagon-Like Peptide-1受体促效剂等先进药物，并结合贴片帮浦和连续血糖监测仪等自动化给药技术，以增强血糖控制。推动此市场发展的关键因素包括：迫切需要能够提高患者依从性的非侵入性治疗方法，以及全球代谢性疾病负担的快速恶化。根据国际糖尿病联盟（IDF）2024年报告，全球约有5.89亿成年人患有糖尿病，这显着增加了对这些先进治疗方法的需求。

然而，这些先进生物製药和医疗设备的高昂成本是市场推广的一大障碍，这不仅限制了注重成本地区的病患取得途径，也造成了庞大的医保报销难题。这种经济障碍，加上复杂组合产品的严格监管核准标准，共同限制了这些治疗方法惠及更广泛患者群体的速度。

市场驱动因素

全球糖尿病和肥胖相关併发症的日益流行，正成为加速整合式医疗服务体系和先进药物干预措施应用的重要催化剂。代谢性疾病的激增促使患者更加依赖新一代治疗方法，尤其是双重GIP和GLP-1受体促效剂，与传统胰岛素疗法相比，这些药物在血糖控制和体重管理方面表现更佳。疾病发生率的上升与这些新型生物製药的商业性成功之间存在直接关联，因为医疗服务提供者优先考虑能够同时控制血糖和减轻体重的治疗方法。礼来公司在2024年第二季财报中指出，其治疗药物Munjaro的全球销售额仅在第二季度就飙升至30.9亿美元，这反映了市场对此类药物的旺盛需求，也凸显了疾病负担在推动创新疗法应用方面所发挥的重要作用。

此外，封闭回路型和自动化胰岛素输注系统的快速发展，满足了患者对持续、微创监测解决方案的需求，从而推动了市场成长。将即时数据分析与自动化输注结合的技术，能够减轻认知负担，并降低手动注射相关的低血糖风险。这些先进设备的广泛应用对于应对更广泛的代谢危机至关重要。值得注意的是，根据世界卫生组织 (WHO) 2024 年的一份报告，肥胖症影响着全球超过 10 亿人，因此对扩充性的治疗方法方案有着巨大的需求。正因如此，製造商们预计这些产品将被广泛应用。根据雅培公司 2024 年第三季的财务业绩，FreeStyle Libre 系统的全球销售额达到 16 亿美元，主要得益于其能够促进个人化照护。

市场挑战

先进糖尿病生技药品和医疗设备的高成本是限制全球下一代糖尿病治疗和药物传输市场成长的一大障碍。儘管自动化输注系统和新型胰岛素类似物能够提供更优的血糖控制，但其高昂的价格使得全球大部分人口，特别是那些自费医疗普遍存在的欠发达地区，难以负担。这种经济差距将目标市场主要限制在富裕人群和拥有广泛医疗保险的人群，使得製造商难以在已开发市场之外拓展业务。

此外，这种经济负担导致保险公司和医疗支付方的审查力度加大，从而製定了严格的报销标准，并减缓了市场渗透率。高昂的现有医疗成本使得支付方不愿意核准昂贵的新治疗方法。根据国际糖尿病联盟（IDF）估计，到2024年，全球与糖尿病相关的医疗成本将达到1.15兆美元。这种严峻的财务压力迫使医疗系统优先考虑成本控制，从而限制了高价值治疗技术的广泛资金筹措和资金投入。

市场趋势

市场正经历着向小型化、无导管、穿戴式贴片帮浦技术的明显转变，从根本上改变了胰岛素的输送机制。与传统的依赖导管的持续释放胰岛素帮浦不同，这些隐藏、防水的设备可直接贴附于皮肤上，为患者提供更大的自由度，并最大限度地减少与可见医疗设备相关的社会污名。这种特殊的外形设计尤其吸引年轻人和生活方式活跃的人群，他们先前由于导管式设备的物理限製而避免使用胰岛素帮浦治疗。这一趋势的商业性成功在Insulet公司2024年第三季的财务业绩中得到了充分体现，该公司报告的营收为5.439亿美元，这主要得益于市场对其无导管自动胰岛素输送平台的强劲需求。

同时，开放式糖尿病生态系统和设备互通性正在迅速发展，实现了不同製造商组件的无缝整合。这一趋势正在打破专有单一品牌系统的局面，使患者能够将自己偏好的胰岛素帮浦与不同的连续血糖监测感测器配对，从而创造出个人化的管理方案。这种柔软性改善了用户体验，并透过消除传统上限制患者选择的硬体相容性障碍，促进了自动化治疗的更广泛应用。为了体现这种互通性策略带来的财务影响，Tandem Diabetes Care 在 2024 年第三季财报中公布了 2.435 亿美元的全球销售额，这主要得益于其胰岛素帮浦平台和多种感测器技术的整合。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球下一代糖尿病治疗与药物传递市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（吸入式胰岛素、口服胰岛素、胰岛素贴片、动态血糖监测系统、人工胰臟）
  • 依适应症（1 型糖尿病、2 型糖尿病）
  • 依最终使用者（诊断/诊所、加护病房(ICU)、家庭医疗保健）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美下一代糖尿病疗法和药物传输市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲下一代糖尿病疗法和药物传输市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区下一代糖尿病疗法和药物传递市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲下一代糖尿病疗法和药物传输市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲新一代糖尿病疗法与药物传递市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

13. 全球下一代糖尿病治疗与药物输送市场：SWOT 分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Abbott Laboratories
• Dexcom Inc.
• Eli Lilly and Company
• Enteris BioPharma Inc.
• GlySens Incorporated
• MannKind Corporation
• Medtronic plc
• Sanofi SA
• Senseonics, Holdings

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Next Generation Diabetes Therapy and Drug Delivery Market is projected to expand from USD 23.86 Billion in 2025 to USD 36.31 Billion by 2031, reflecting a compound annual growth rate of 7.25%. This sector encompasses advanced pharmacological agents, including novel insulin analogs and glucagon-like peptide-1 receptor agonists, integrated with automated administration technologies such as patch pumps and continuous glucose monitors to enhance glycemic regulation. The primary factors driving this market include the urgent requirement for non-invasive treatment alternatives that boost patient compliance and the rapidly escalating global burden of metabolic conditions. As reported by the International Diabetes Federation in 2024, roughly 589 million adults globally were living with diabetes, generating substantial demand for these sophisticated therapeutic interventions.

However, a major obstacle hindering market progression is the prohibitive expense associated with these advanced biologics and devices, which restricts access in cost-conscious regions and creates significant reimbursement difficulties. This economic hurdle, coupled with rigorous regulatory standards for approving complex combination products, limits the pace at which these therapies become available to the broader patient population.

Market Driver

The rising global prevalence of diabetes and obesity-related comorbidities acts as a major catalyst accelerating the adoption of integrated delivery systems and advanced pharmacological interventions. This surge in metabolic disorders drives patient dependence on next-generation therapies, specifically dual GIP and GLP-1 receptor agonists, which deliver superior glycemic control and weight management compared to conventional insulin regimens. A direct correlation exists between increasing disease incidence and the commercial success of these novel biologics, as healthcare providers prioritize treatments that address both glucose regulation and weight reduction. Reflecting this high demand, Eli Lilly and Company reported in their Q2 2024 financial results that worldwide revenue for the therapy Mounjaro jumped to $3.09 billion in the second quarter alone, highlighting the role of disease burden in driving the uptake of innovative formulations.

Furthermore, rapid advancements in closed-loop and automated insulin delivery systems stimulate market growth by meeting the growing patient need for continuous, minimally invasive monitoring solutions. Technologies merging real-time data analytics with automated dosing alleviate the cognitive load on patients and lower hypoglycemia risks associated with manual injections. The proliferation of these sophisticated devices is crucial for managing the wider metabolic crisis, particularly given the World Health Organization's 2024 report that over 1 billion people worldwide were living with obesity, creating a vast need for scalable therapeutic options. Consequently, manufacturers are seeing strong adoption; Abbott's Third Quarter 2024 financial results indicated global sales of the FreeStyle Libre system reached $1.6 billion, driven by its ability to facilitate personalized care.

Market Challenge

The high cost associated with advanced diabetes biologics and devices represents a significant barrier that directly hampers the growth of the Global Next Generation Diabetes Therapy and Drug Delivery Market. Although automated delivery systems and novel insulin analogs provide superior glycemic control, their elevated price points make them inaccessible to a large portion of the global population, especially in developing regions where out-of-pocket payment is common. This economic disparity limits the addressable market primarily to affluent demographics or those with extensive insurance coverage, making it difficult for manufacturers to scale adoption rates outside of developed markets.

Moreover, this financial burden leads to intensified scrutiny from insurance providers and healthcare payers, resulting in strict reimbursement criteria that delay market penetration. The immense scale of existing costs makes payers reluctant to approve expensive new therapies. According to the International Diabetes Federation, diabetes accounted for an estimated USD 1.015 trillion in global health expenditure in 2024. This profound financial strain compels healthcare systems to prioritize cost containment, thereby restricting the widespread funding and uptake of premium therapeutic technologies.

Market Trends

The market is witnessing a distinct shift toward miniaturized and tubeless wearable patch pump technologies, which are fundamentally transforming insulin delivery mechanisms. In contrast to traditional durable pumps that rely on tubing, these discreet, waterproof devices adhere directly to the skin, offering patients increased freedom and minimizing the stigma often associated with visible medical equipment. This specific form factor is particularly appealing to younger demographics and individuals with active lifestyles who previously avoided pump therapy due to the physical limitations of tubed devices. The commercial viability of this trend is evident in Insulet Corporation's Third Quarter 2024 financial results, where revenue hit $543.9 million, largely driven by high demand for their tubeless automated insulin delivery platform.

Concurrently, there is a rapid expansion of open-architecture diabetes ecosystems and device interoperability, facilitating the seamless integration of components from various manufacturers. This trend moves away from proprietary, single-brand systems, allowing patients to pair their preferred insulin pumps with different continuous glucose monitoring sensors to create customized management solutions. This flexibility improves user experience and promotes broader adoption of automated therapy by eliminating hardware compatibility barriers that formerly restricted patient choice. Reflecting the financial impact of this cross-compatibility strategy, Tandem Diabetes Care reported in their Third Quarter 2024 financial results that worldwide sales totaled $243.5 million, bolstered by the integration of their pump platforms with multiple sensor technologies.

Key Market Players

• Abbott Laboratories
• Dexcom Inc.
• Eli Lilly and Company
• Enteris BioPharma Inc.
• GlySens Incorporated
• MannKind Corporation
• Medtronic plc
• Sanofi S.A.
• Senseonics, Holdings

Report Scope

In this report, the Global Next Generation Diabetes Therapy and Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Diabetes Therapy and Drug Delivery Market, By Product Type

• Inhalable Insulin
• Oral Insulin
• Insulin Patches
• CGM Systems
• Artificial Pancreas

Next Generation Diabetes Therapy and Drug Delivery Market, By Indication

• Type 1 diabetes
• Type 2 diabetes

Next Generation Diabetes Therapy and Drug Delivery Market, By End user

• Diagnostic/Clinics
• Intensive Care Units (ICUs)
• Home Healthcare

Next Generation Diabetes Therapy and Drug Delivery Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Diabetes Therapy and Drug Delivery Market.

Available Customizations:

Global Next Generation Diabetes Therapy and Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next Generation Diabetes Therapy and Drug Delivery Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas)
  • 5.2.2. By Indication (Type 1 diabetes, Type 2 diabetes)
  • 5.2.3. By End user (Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Next Generation Diabetes Therapy and Drug Delivery Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Indication
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End user

7. Europe Next Generation Diabetes Therapy and Drug Delivery Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Indication
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End user
  • 7.3.2. France Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End user

8. Asia Pacific Next Generation Diabetes Therapy and Drug Delivery Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Indication
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End user
  • 8.3.2. India Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End user

9. Middle East & Africa Next Generation Diabetes Therapy and Drug Delivery Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Indication
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End user

10. South America Next Generation Diabetes Therapy and Drug Delivery Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Indication
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Next Generation Diabetes Therapy and Drug Delivery Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Next Generation Diabetes Therapy and Drug Delivery Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Dexcom Inc.
• 15.3. Eli Lilly and Company
• 15.4. Enteris BioPharma Inc.
• 15.5. GlySens Incorporated
• 15.6. MannKind Corporation
• 15.7. Medtronic plc
• 15.8. Sanofi S.A.
• 15.9. Senseonics, Holdings

16. Strategic Recommendations

17. About Us & Disclaimer